AFT Pharmaceuticals Limited (NZE:AFT)

Market Cap	369.13M
Revenue (ttm)	236.25M
Net Income (ttm)	17.45M
Shares Out	104.87M
EPS (ttm)	0.16
PE Ratio	21.75
Forward PE	22.22
Dividend	0.02 (0.51%)
Ex-Dividend Date	Jun 18, 2025

Volume	18,606
Average Volume	20,985
Open	3.630
Previous Close	3.630
Day's Range	3.500 - 3.630
52-Week Range	2.410 - 3.750
Beta	0.45
RSI	60.99
Earnings Date	Nov 19, 2025

About AFT Pharmaceuticals

AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, pain management, skin care, vitamins, supplements, gastrointestinal, dermatology, and hospital. It has a research and development collaboration with Belgium’s Hyloris Pharmaceuticals to develop a novel innovative injecta...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 119
• Stock Exchange: New Zealand Stock Exchange
• Ticker Symbol: AFT

Financial Performance

In 2024, AFT Pharmaceuticals's revenue was 208.02 million, an increase of 6.45% compared to the previous year's 195.41 million. Earnings were 11.96 million, a decrease of -23.36%.